Ipragliflozin as an add-on therapy in type 2 diabetes mellitus patients: An evidence-based pharmacoeconomics evaluation
2019 ◽
Vol 157
◽
pp. 107867
Keyword(s):
2021 ◽
Vol 13
(03)
◽
2020 ◽
Keyword(s):
Keyword(s):
Keyword(s):